Pioneering discovery and therapeutics at the brain-vascular-immune interface

Katerina Akassoglou¹, Dimitrios Davalos², Andrew S Mendiola³, Mark A Petersen⁴, Jae Kyu Ryu⁵, Christian Schachtrup⁶, Zhaoqi Yan⁷

Affiliations

¹ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: kakassoglou@gladstone.ucsf.edu.
² Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44106, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA.
³ Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
⁴ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94158, USA.
⁵ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
⁶ Institute of Anatomy and Cell Biology, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Center for Basics in NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁷ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.

PMID: 39423805
DOI: 10.1016/j.cell.2024.09.018

Pioneering discovery and therapeutics at the brain-vascular-immune interface

Katerina Akassoglou et al. Cell. 2024.

. 2024 Oct 17;187(21):5871-5876.

doi: 10.1016/j.cell.2024.09.018.

Authors

Katerina Akassoglou¹, Dimitrios Davalos², Andrew S Mendiola³, Mark A Petersen⁴, Jae Kyu Ryu⁵, Christian Schachtrup⁶, Zhaoqi Yan⁷

Affiliations

¹ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: kakassoglou@gladstone.ucsf.edu.
² Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44106, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA.
³ Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
⁴ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94158, USA.
⁵ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
⁶ Institute of Anatomy and Cell Biology, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Center for Basics in NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁷ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.

PMID: 39423805
DOI: 10.1016/j.cell.2024.09.018

Abstract

The brain-vascular-immune interface has emerged as a dynamic player in brain physiology and disease. We propose integrating vascular risk factors with genetic susceptibility as the nexus for the discovery of mechanisms and therapies for neuroinflammation, neurodegeneration, and neurorepair across polygenic neurologic diseases.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests K.A. is the scientific founder and scientific advisor of Therini Bio and has served as a consultant for F. Hoffman-La Roche and Sanofi. K.A., J.K.R., and M.A.P. are inventors on issued and pending patents related to fibrin. Their interests are managed in accordance with Gladstone Institute’s conflict of interest policies.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pioneering discovery and therapeutics at the brain-vascular-immune interface

Affiliations

Pioneering discovery and therapeutics at the brain-vascular-immune interface

Authors

Affiliations

Abstract

Conflict of interest statement

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources